Systemic treatments for metastatic cutaneous melanoma
- 24 April 2000
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 2,p. CD001215
- https://doi.org/10.1002/14651858.cd001215
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.Journal of Clinical Oncology, 1994
- Treatment of Metastatic Malignant Melanoma with Dacarbazine plus TamoxifenNew England Journal of Medicine, 1992
- Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.Journal of Clinical Oncology, 1991
- Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: A randomized phase II studyMedical Oncology and Tumor Pharmacotherapy, 1989
- Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanomaInvestigational New Drugs, 1984
- Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.Journal of Clinical Oncology, 1984
- Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosoureaCancer, 1972
- Combination Phase 1 -II Study of Imidazole Carboxamide (NCS 45388)Oncology, 1972
- Characteristics of prognosis and response to an imidazole carboxamide in malignant melanomaClinical Pharmacology & Therapeutics, 1971
- Clinical Evaluation of 5-(3,3-Dimethyl-1-Triazeno) Imidazole-4-Carboxamide in Malignant Melanoma and Other Neoplasms: Comparison of Twice-weekly and Daily Administration SchedulesOncology, 1971